{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T11:24:47Z","timestamp":1777289087935,"version":"3.51.4"},"reference-count":24,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Case Reports"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The COVID\u201019 pandemic highlighted the benefits of subcutaneous (SC) administration for healthcare systems. The first SC infliximab, CT\u2010P13 SC, was safe and effective for the treatment of psoriatic arthritis. Observed patient preferences for continuing CT\u2010P13 SC suggest that patients receiving IV infliximab should be offered a switch to CT\u2010P13 SC.<\/jats:p>","DOI":"10.1002\/ccr3.5205","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T05:24:38Z","timestamp":1642742678000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Real\u2010world evidence for subcutaneous infliximab (CT\u2010P13 SC) treatment in patients with psoriatic arthritis during the coronavirus disease (COVID\u201019) pandemic: A case series"],"prefix":"10.1002","volume":"10","author":[{"given":"Xenofon","family":"Baraliakos","sequence":"first","affiliation":[{"name":"Ruhr\u2010Universit\u00e4t Bochum Rheumazentrum Ruhrgebiet Herne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Styliani","family":"Tsiami","sequence":"additional","affiliation":[{"name":"Ruhr\u2010Universit\u00e4t Bochum Rheumazentrum Ruhrgebiet Herne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sooraj","family":"Vijayan","sequence":"additional","affiliation":[{"name":"Department of Rheumatology New Cross Hospital Royal Wolverhampton NHS Trust Wolverhampton UK"},{"name":"SUT Academy of Medical Sciences Thiruvananthapuram India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haewon","family":"Jung","sequence":"additional","affiliation":[{"name":"Celltrion Healthcare Co., Ltd Incheon Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7754-6931","authenticated-orcid":false,"given":"Nick","family":"Barkham","sequence":"additional","affiliation":[{"name":"Department of Rheumatology New Cross Hospital Royal Wolverhampton NHS Trust Wolverhampton UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,1,20]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis\u20102020\u2010217159"},{"key":"e_1_2_10_3_1","unstructured":"National Institute for Health and Care Excellence.Spondyloarthritis in over 16s: diagnosis and management.2017. Available at:https:\/\/www.nice.org.uk\/guidance\/ng65\/resources\/spondyloarthritis\u2010in\u2010over\u201016s\u2010diagnosis\u2010and\u2010management\u2010pdf\u20101837575441349Accessed 6 April 2021."},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket187"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39573"},{"key":"e_1_2_10_6_1","unstructured":"European Medicines Agency.Remsima summary of product characteristics.2021. Available at:https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/remsima\u2010epar\u2010product\u2010information_en.pdfAccessed 19 March 2021"},{"key":"e_1_2_10_7_1","unstructured":"European Medicines Agency.Remicade summary of product characteristics.2020. Available at:https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/remicade\u2010epar\u2010product\u2010information_en.pdfAccessed 23 March 2021"},{"key":"e_1_2_10_8_1","unstructured":"European Medicines Agency.Inflectra summary of product characteristics.2020. Available at:https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/inflectra\u2010epar\u2010product\u2010information_en.pdfAccessed 23 March 2021"},{"key":"e_1_2_10_9_1","unstructured":"US Food and Drug Administration.Inflectra prescribing information.2019. Available at:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125544s009lbl.pdfAccessed 23 March 2021"},{"key":"e_1_2_10_10_1","unstructured":"US Food and Drug Administration.Remicade prescribing information.2020. Available at:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/103772s5389s5391s5394lbl.pdfAccessed 23 March 2021"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2020.1868078"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa580"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.02.068"},{"key":"e_1_2_10_14_1","unstructured":"Biosimilar Development.European Commission grants marketing authorisation for world's first subcutaneous formulation of infliximab Remsima SC for an additional five indications including for use in inflammatory bowel disease and ankylosing spondylitis.2020. Available at:https:\/\/www.biosimilardevelopment.com\/doc\/european\u2010commission\u2010grants\u2010marketing\u2010authorisation\u2010for\u2010world\u2010s\u2010first\u2010subcutaneous\u20100001Accessed 16 April 2021."},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.201017"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab174"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen\u20102020\u2010001505"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis\u20102020\u2010217953"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis\u20102020\u2010217806"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis\u20102020\u2010219498"},{"key":"e_1_2_10_21_1","unstructured":"National Institute for Health and Care Excellence.COVID\u201019 rapid guideline: rheumatological autoimmune inflammatory and metabolic bone disorders.2020. Available at:https:\/\/www.nice.org.uk\/guidance\/ng167\/resources\/covid19\u2010rapid\u2010guideline\u2010rheumatological\u2010autoimmune\u2010inflammatory\u2010and\u2010metabolic\u2010bone\u2010disorders\u2010pdf\u201066141905788357Accessed 22 March 2021"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477\u20107525\u20109\u20102"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259\u2010018\u20100306\u20101"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa653"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis\u20102020\u2010217877"}],"container-title":["Clinical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ccr3.5205","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ccr3.5205","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ccr3.5205","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T10:25:49Z","timestamp":1693218349000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ccr3.5205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1002\/ccr3.5205"],"URL":"https:\/\/doi.org\/10.1002\/ccr3.5205","archive":["Portico"],"relation":{},"ISSN":["2050-0904","2050-0904"],"issn-type":[{"value":"2050-0904","type":"print"},{"value":"2050-0904","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"2021-10-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e05205"}}